Follow us on:

N4 Pharma could attract a corporate partner far earlier than expected says SP Angel (Analyst Interview)

N4 Pharma plc (LON:N4P) is the topic of conversation when SP Angel Analyst and Head of Healthcare Vadim Alexandre joins DirectorsTalk. Vadim having just initiated on the company explains what N4P does, the particular areas the business is involved in, the current workstreams, how the covid pandemic has affected the company and where Vadim sees value in the company.

N4 Pharma are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.

Find more news, interviews, share price & company profile here for:

Share this interview

Other Interviews

N4 Pharma Nuvec technology could be used for multiple vaccines not just Covid-19 (Interview) September 14, 2020

More News

N4 Pharma launch Interactive Investor Hub November 30, 2023
N4 Pharma updated investor presentation October 2, 2023
N4 Pharma acquires of a controlling interest in Nanogenics September 28, 2023
N4 Pharma granting of patent application in the United States July 25, 2023
N4 Pharma Chengzhong Yu awarded grant to work on patented nuvec® nanoparticle June 27, 2023
N4 Pharma testing to generate dose response curve for BCL-2 studies April 25, 2023
N4 Pharma very pleased with EGFR results April 18, 2023
N4 Pharma to now start business development outreach of its siRNA data March 9, 2023
Stocks making the news: N4 Pharma, Union Jack Oil, Renold Plc, hVIVO and R&Q Insurance January 17, 2023
N4 Pharma provides update on ongoing Australian Research Council grant work January 17, 2023

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.